Tremfya is supplied in a single-dose vial (200mg/20mL) for IV infusion and in a single-dose prefilled syringe (100mg/mL, 200mg/2mL), single-dose prefilled pen (200mg/2mL), or single-dose One-Press ...

MONDAY, March 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This approval is ...

TREMFYA ® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study ...

Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the ...

Johnson & Johnson’s (J&J) Tremfya (guselkumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with moderately to severely active Crohn’s disease (CD). CD is one of the ...

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic ... with less frequent dosing during the maintenance phase of treatment, and competitive pricing.

56% of Tremfya patients achieved clinical remission compared to just 22% of those in the control arm. The drug performed similarly well in the induction setting at an infused, 200-mg dose ...